Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BB-401 in Recurrent or Metastatic HNSCC
NCT03433027Phase 2Completed
- Sponsor
- Benitec Biopharma Inc.
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, Small Interfering RNA (siRNA)
- Countries
- 2
01
Overview
A Phase 2 trial of BB-401 in head and neck squamous cell carcinoma (HNSCC), sponsored by Benitec Biopharma Inc.. Started Mar 2018; status: completed.
02
Drugs
BB-401
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03433027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03433027.